BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9292744)

  • 1. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease.
    Gustavsson A
    Acta Oncol; 1997; 36(5):483-8. PubMed ID: 9292744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadal function following ABVD therapy for Hodgkin's disease.
    Kulkarni SS; Sastry PS; Saikia TK; Parikh PM; Gopal R; Advani SH
    Am J Clin Oncol; 1997 Aug; 20(4):354-7. PubMed ID: 9256888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.
    Dunlop DJ; Eatock MM; Paul J; Anderson S; Reed NS; Soukop M; Lucie N; Fitzsimmons EJ; Tansey P; Steward WP
    Clin Oncol (R Coll Radiol); 1998; 10(2):107-14. PubMed ID: 9610900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy.
    van den Berg H; Stuve W; Behrendt H
    Med Pediatr Oncol; 1997 Jul; 29(1):23-7. PubMed ID: 9142201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy.
    Cantin G; L'Espérance B; Yelle L; Desjardins L; Couture F; Bergeron M; Lacroix L; Dufresne J; Bélanger D; Ouellet PA; Hewitt LA; Pirc L; Gyger M
    Cancer Chemother Pharmacol; 1999; 43(6):503-6. PubMed ID: 10321511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD.
    Rueda A; Sevilla I; Gumà J; Ribelles N; Miramón J; De Las Nieves MA; Márquez A; Alba E
    Leuk Lymphoma; 2001 Apr; 41(3-4):353-8. PubMed ID: 11378548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
    Harker WG; Kushlan P; Rosenberg SA
    Ann Intern Med; 1984 Oct; 101(4):440-6. PubMed ID: 6206757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
    J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.
    Ng AK; Li S; Neuberg D; Silver B; Stevenson MA; Fisher DC; Mauch PM
    Ann Oncol; 2004 Feb; 15(2):270-5. PubMed ID: 14760121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.